FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298037534> ?p ?o ?g. }

• W4298037534 endingPage "89" @default.
• W4298037534 startingPage "677" @default.
• W4298037534 abstract "This Memorandum reviews the results of research undertaken in animals and human subjects on once-a-month injectable contraceptives containing a progestogen and an estrogen, in particular the products Cyclofem and Mesigyna. Results from clinical trials, including effectiveness and side-effects, are evaluated and issues arising from health service research are discussed. The Memorandum concludes with a statement regarding the use of Cyclofem and Mesigyna as options for potential contraceptive users.Experts met in June 1993 at WHO headquarters in Geneva to review animal and research findings on once-a-month injectable contraceptives with a progestogen and an estrogen, especially Cyclofem and Mesigyna. Two widely used injectable contraceptives are the Chinese Injectable No. 1 (250 mg 17alpha-hydroxyprogesterone caproate + 5 mg estradiol valerate) and an injectable with 150 mg dihydroxyprogesterone acetophenide + 10 mg estradiol enanthate used in Latin America. Two new combined once-a-month injectables are Cyclofem (25 mg medroxyprogesterone acetate + 5 mg estradiol cypionate) and Mesigyna (50 mg norethindrone enanthate + 5 mg estradiol valerate). The aforementioned doses are based on high efficacy and acceptable vaginal bleeding patterns. Pregnancy life table rates in 5 clinical phase III trials in 9793 women (102,058 woman-months of use) are all below 0.4% for Mesigyna and 0.2% for Cyclofem. More than 65% had normal menstrual cycles. Discontinuations for menstrual irregularities were 50% less than those of progestogen only injectables. Discontinuation rates for amenorrhea were low. The limited data on return to ovulation suggest that ovulation occurs within a few months of discontinuation. No safety concerns have been evident in the animal studies. Long term data on humans on the once-a-month injectables and cancer do not yet exist. The incidence of side effects is low. Studies of Cyclofem in 6 countries with more than 9000 women have examined management and service issues and medical surveillance. Identified needs are adequate patient information, staff trained in new methods, monthly injectables as a free choice of contraceptive methods, proper distribution and storage, and adequate supplies. As long has all potential risk factors are taken into account, Cyclofem and Mesigyna are safe and effective." @default.
• W4298037534 created "2022-10-01" @default.
• W4298037534 date "1993-01-01" @default.
• W4298037534 modified "2023-09-29" @default.
• W4298037534 title "Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting." @default.
• W4298037534 cites W1430861621 @default.
• W4298037534 cites W14389034 @default.
• W4298037534 cites W1588945805 @default.
• W4298037534 cites W1963641875 @default.
• W4298037534 cites W1966861675 @default.
• W4298037534 cites W1984559522 @default.
• W4298037534 cites W2001927881 @default.
• W4298037534 cites W2002800082 @default.
• W4298037534 cites W2048033256 @default.
• W4298037534 cites W2054258725 @default.
• W4298037534 cites W2055054480 @default.
• W4298037534 cites W2060009461 @default.
• W4298037534 cites W2060269724 @default.
• W4298037534 cites W2062893281 @default.
• W4298037534 cites W2065922977 @default.
• W4298037534 cites W2074393285 @default.
• W4298037534 cites W2090703237 @default.
• W4298037534 cites W2091603682 @default.
• W4298037534 cites W2109222007 @default.
• W4298037534 cites W2111519803 @default.
• W4298037534 cites W2124931525 @default.
• W4298037534 cites W2138050543 @default.
• W4298037534 cites W2268574046 @default.
• W4298037534 cites W2268772181 @default.
• W4298037534 cites W2297217204 @default.
• W4298037534 cites W2408259604 @default.
• W4298037534 cites W2514826818 @default.
• W4298037534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8313486" @default.
• W4298037534 hasPublicationYear "1993" @default.
• W4298037534 type Work @default.
• W4298037534 citedByCount "2" @default.
• W4298037534 countsByYear W42980375342021 @default.
• W4298037534 crossrefType "journal-article" @default.
• W4298037534 hasConcept C126322002 @default.
• W4298037534 hasConcept C131872663 @default.
• W4298037534 hasConcept C2776306185 @default.
• W4298037534 hasConcept C2777164284 @default.
• W4298037534 hasConcept C2777702977 @default.
• W4298037534 hasConcept C2778001906 @default.
• W4298037534 hasConcept C2778715236 @default.
• W4298037534 hasConcept C2780572241 @default.
• W4298037534 hasConcept C2908647359 @default.
• W4298037534 hasConcept C29456083 @default.
• W4298037534 hasConcept C71315377 @default.
• W4298037534 hasConcept C71924100 @default.
• W4298037534 hasConcept C99454951 @default.
• W4298037534 hasConceptScore W4298037534C126322002 @default.
• W4298037534 hasConceptScore W4298037534C131872663 @default.
• W4298037534 hasConceptScore W4298037534C2776306185 @default.
• W4298037534 hasConceptScore W4298037534C2777164284 @default.
• W4298037534 hasConceptScore W4298037534C2777702977 @default.
• W4298037534 hasConceptScore W4298037534C2778001906 @default.
• W4298037534 hasConceptScore W4298037534C2778715236 @default.
• W4298037534 hasConceptScore W4298037534C2780572241 @default.
• W4298037534 hasConceptScore W4298037534C2908647359 @default.
• W4298037534 hasConceptScore W4298037534C29456083 @default.
• W4298037534 hasConceptScore W4298037534C71315377 @default.
• W4298037534 hasConceptScore W4298037534C71924100 @default.
• W4298037534 hasConceptScore W4298037534C99454951 @default.
• W4298037534 hasIssue "6" @default.
• W4298037534 hasLocation W42980375341 @default.
• W4298037534 hasOpenAccess W4298037534 @default.
• W4298037534 hasPrimaryLocation W42980375341 @default.
• W4298037534 hasRelatedWork W1644346105 @default.
• W4298037534 hasRelatedWork W2018187287 @default.
• W4298037534 hasRelatedWork W2075822341 @default.
• W4298037534 hasRelatedWork W2109222007 @default.
• W4298037534 hasRelatedWork W2122406834 @default.
• W4298037534 hasRelatedWork W2131694043 @default.
• W4298037534 hasRelatedWork W2171404744 @default.
• W4298037534 hasRelatedWork W2308708467 @default.
• W4298037534 hasRelatedWork W2338124628 @default.
• W4298037534 hasRelatedWork W2219879519 @default.
• W4298037534 hasVolume "71" @default.
• W4298037534 isParatext "false" @default.
• W4298037534 isRetracted "false" @default.
• W4298037534 workType "article" @default.